After 4 cycles of salvage chemotherapy with rituximab, gemcitabine, and oxaliplatin, the patient underwent CAR T‐cell therapy with axi‐cel with a CR, and achieved sustained remission for nearly 1 year123 In an analysis of CD19 expression in tumor lymph node biopsies from six patients with R/R DLBCL treated with tafasitamab plus lenalidomide in the L‐MIND study, immunohistochemistry showed distinct CD19 expression in all 12 pre‐ and post‐treatment biopsies, independent of treatment duration/response, or potential residual tafasitamab exposure. Here, CD19 is linked to neoplasm.